who hard of thank you, global Amneal worked to morning. healthy Good mission our advance making possible and Chirag, for patients. day the you to every Thank family
areas differentiated well on building sustainable As Chirag innovative, we growth diversified in been have discussed, of of X focused company last medicine. key driving these and capable global pharmaceuticals years an
in outlook very and half ahead. strong of are about the excited We XXXX the first performance our
R&D to and propel will I how touch our excellence, continue chain supply highly success. productive on operational expanded capabilities our engine, resilient
driving First, we and operational on efficiency. excellence remain focused
opportunities to example, XX bring evaluating we continuously process products cost of moving to for down. we As in the and locations, production are an lower-cost are about
in global our resiliency and operations. In by our redundancy adding addition, key strengthened our have we supply areas, infrastructures of expanding chain
operations X production have where facilities global notably, at benefit to Most XX support our long-term the in Importantly, today, scale with see we growth. are we injectables, lines.
the last doubled continued chronic have face the capacity. shortages. time, same market At the supply few to we Over our overall years, injectables injectables
As products U.S. ANDAs, and are on we at with pending portfolio look shortage XX XX the pipeline. our list FDA commercial additional our
shortages is supply with help and drug chain Amneal positioned our well States. address the expanded capacity United to in
In our footprint expand addition, capabilities. build our we and
are the We our XX FDA year successful quality including has track no XXXs. maintaining XXXX, with X record. committed Since minor inspections, U.S. observations or conducted this to
R&D. generics to Moving
portfolio medicines. made complex our have tremendous diversifying progress with new We
includes this on XXXX. are XX% XX X we XX our over launched new to FDA track solid We with products. and XX we our approval, have in year, high-value so injectables, categories. have products. products Behind pipeline XX new shifted launch non-oral diversified X topicals we far have that, Overall, complex being and pending have This representing XX inhalation incrementally XX products well-established we products portfolio, with ophthalmics, focus and solids. With non-oral XX% to ANDAs
of fact, are to pipeline first-to-file XX% pending or XXX(b)(X) our XX% ANDAs of opportunities. and In expected first-to-market, be
high-value Plerixafor launched and bimatoprost Proair year-to-date. X launched facilities July, the These of have and In LVP generics, are inhalation, we our on. In injectables. announced including ANDA products generic new one in we Injectables, injectable recently, are of of X emulsion we X focused products oncology R&D propofol and in new the first sulfate ophthalmics, indicative filing bag our in complex we programs most injectables. from magnesium Most
a other QX. in advancing injectables are first expect our and number We XXX(b)(X) file X of complex to ready-to-use bags
the XXXX, new strong cadence in of expect including XXXX. January in and injectables We launch XXXX PEMRYDI RTU a of
for After key ahead are very We injectables, in growth Amneal. Amneal’s excited injectables inhalation the about and complex see we in opportunity generics. area next
inhalation Both to high-valued QVAR in programs Further, upon launch key inhaler have dose platform. expected approval. MDI pending We Proair. generic Mist in are with technology are metered we as are devices utilizing two Other Soft several generic developing the development XXXX well. ANDAs Respimat and
me launches highlight currently Let underway. now key
First, we authorized Xyrem an July. version generic launched of in
set QX. medicine are key ADHD in we Second, Lisdexamfetamine, launch to a
pending Narcan ANDA under our is generic priority for review. Third,
overdose this of A critical access very included We our on treatment. will over-the-counter our is planned list which broader notable are slide. passionate to a life-saving launches product, improve catalyst opioid about
are very space. in excited the about this for in we Amneal Next, biosimilar, potential
biosimilars to for further expand long-term We and as partnerships portfolio see a oncology biosimilar uptake seeing first through excellent molecules. key compelling our Our opportunity a there is growth are driver.
Turning to pipeline. to XXX(b)(X) advance continue work our specialty R&D, we to
disclosed, safety the we to related received requested we CRL carbidopa. of IPXXXX data the additional for for As scientific breach the
provide the FDA We data necessary approval. We the expect address launch IPXXXX Type comments to to look A following meeting have to few a next with in and weeks.
are fueling IPXXXX and growth. our are advances innovation We ability an with Parkinson’s drive driving on to continue patients. care as broad excellence for to which a of innovation strategy, together standard the executing see In we summary, appeal operational sustainable our that
over now will to I it hand Tasos.
